Updates are available Correction dated 2026-04-16
Click to view Correction: https://doi.org/10.1038/s41386-026-02411-4
-
Authors
Harvey, Philip D. https://orcid.org/0000-0002-9501-9366
Nemeroff, Charles B. https://orcid.org/0000-0001-7867-1160
- License Information
-
More Information
Article History
Received: 26 June 2025
Revised: 7 August 2025
Accepted: 11 August 2025
First Online: 16 January 2026
Change Date: 13 April 2026
Change Type: Update
Change Details: The original online version of this article was revised: Adapted from Mian et al. (2025), with permission. has been added to the Fig. 1 caption.
Change Date: 16 April 2026
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41386-026-02411-4
Competing interests
: Philip D Harvey is supported by the National Institutes of Aging, the National Institute of Mental Health, and the US Department of Veterans Affairs. He has received consulting fees or travel reimbursements from Alkermes, BMS (Karuna Therapeutics), Boehringer Ingelheim, Kynexis, Minerva Neurosciences, and Neurocrine Biosciences. He has a research grant from Intracellular Therapeutics (Now part of Johnson and Johnson). He receives royalties from the Brief Assessment of Cognition in Schizophrenia (Currently owned by Clario, Inc. and contained in the MCCB). He is the chief scientific officer of i-Function, Inc. and a Scientific Consultant to EMA Wellness, Inc. Charles B Nemeroff is supported by the National Institutes of Health, the National Institute of Mental Health, the Texas Child Mental Health Consortium, and the National Institute of Alcohol Abuse and Alcoholism. Charles Nemeroff is a consultant for Engrail Therapeutics, Clexio Biosciences LTD, Galen Mental Health LLC, Goodcap Pharmaceuticals, ITI Inc, Sage Therapeutics, Senseye Inc, Precisement Health, Autobahn Therapeutics Inc, EMA Wellness, Denovo Biopharma LLC, Alvogen, Acadia Pharmaceuticals, Inc, Reunion Neuroscience, Kivira Health, Inc, Wave Neuroscience, Patient Square Capital LP, Invisalert Solutions Inc., and Neurocrine Biosciences, LLC. Charles Nemeroff owns the following patents: Method and devices for transdermal delivery of lithium (US 6,375,990B1), Method of assessing antidepressant drug therapy via transport inhibition of monoamine neurotransmitters by ex vivo assay (US 7,148,027B2), Compounds, Compositions, Methods of Synthesis, and Methods of Treatment (CRF Receptor Binding Ligand) (US 8,551,996B2). Charles Nemeroff owns stock in Corcept Therapeutics Company, EMA Wellness, Precisement Health, Signant Health, Galen Mental Health LLC, Kivira Health, Inc., Denovo Biopharma LLC, and Senseye Inc.
